Innovative drugs from multinationals gain wider insurance coverage in China

Publish Date:2026-11-19     Source:China Daily

Multinational pharmaceutical companies have secured broader coverage for their innovative medicines under China's updated national medical insurance drug list and a separate commercial health insurance list for innovative drugs, a move expected to make more treatments accessible and affordable to patients.

Both lists will take effect on Jan 1, 2027. The National Healthcare Security Administration has revised the national medical insurance drug list annually for nine consecutive years.

AstraZeneca said 13 of its medicines were affected by the adjustments across the two lists. Two drugs entered the basic insurance list for the first time, including tezepelumab for severe asthma and certain patients with chronic rhinosinusitis with nasal polyps, and datopotamab deruxtecan for certain patients with advanced breast cancer.

Another 11 indications involving five AstraZeneca medicines gained basic insurance coverage, including five additional indications for trastuzumab deruxtecan in breast, gastric and lung cancers.

Sanofi said six of its medicines, including treatments with newly covered indications, were included across the two lists. Among them were rovadicitinib, a China-developed treatment for myelofibrosis out-licensed globally to Sanofi by Chia Tai Tianqing, a subsidiary of Sino Biopharm,and aficamten, a treatment for obstructive hypertrophic cardiomyopathy.

Novo Nordisk's once-weekly combination injection of insulin icodec and semaglutide was also added to the basic insurance list for eligible adults with type 2 diabetes whose blood sugar remains inadequately controlled after certain treatments with basal insulin or a GLP-1 receptor agonist.

China was the first market to commercially launch the combination treatment, which brings together a long-acting insulin and a GLP-1 receptor agonist in a single weekly injection, according to Novo Nordisk.

Astellas Pharma's targeted stomach cancer drug zolbetuximab was also added to the national medical insurance drug list, a move expected to make the treatment more affordable for eligible patients.

The drug, marketed as Vyloy, is the only CLDN18.2-targeted therapy included in the national  insurance list, according to the company. It is used alongside chemotherapy as a first-line treatment for patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer.

Around 35 percent of Chinese patients with advanced gastric or gastroesophageal junction cancer test positive for CLDN18.2, a protein found on certain cancer cells, according to data cited by Astellas.

The National Medical Products Administration approved zolbetuximab in December 2024, and its first prescriptions were issued in several Chinese cities in June 2025.

Shirley Zhao, president of Astellas China, said the inclusion reflected China's continued support for pharmaceutical innovation and efforts to improve patients' access to new treatments.

"We are pleased to see scientific innovation being translated more rapidly into treatment options accessible to more patients in China," Zhao said.